Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury.

Publication ,  Journal Article
Privratsky, JR; Ide, S; Chen, Y; Kitai, H; Ren, J; Fradin, H; Lu, X; Souma, T; Crowley, SD
Published in: Kidney Int
March 2023

The most common cause of acute kidney injury (AKI) in critically ill patients is sepsis. Kidney macrophages consist of both F4/80hi and CD11bhi cells. The role of macrophage subpopulations in septic AKI pathogenesis remains unclear. As F4/80hi macrophages are reported to contribute to immunomodulation following injury, we hypothesized that selective depletion of F4/80hi macrophages would worsen septic AKI. F4/80hi macrophages were depleted via diphtheria toxin injection in CD11cCre(+)/CX3CR1dtr/wt (F4/80 MKO mice) compared to CD11cCre(-)/CX3CR1dtr/wt (F4/80 MWT) mice. F4/80 MWT and F4/80 MKO mice were subjected to sham or cecal ligation and puncture to induce sepsis. Compared to F4/80 MWT mice, F4/80 MKO mice displayed worsened septic AKI at 24 hours as measured by serum creatinine and histologic injury scoring. Kidneys from F4/80 MKO mice elaborated higher kidney interleukin-6 levels. Mechanistically, single cell RNA sequencing identified a macrophage-endothelial cell immunoregulatory axis that underlies interleukin-6 expression. F4/80hi macrophages expressed interleukin-1 receptor antagonist and limited interleukin-6 expression in endothelial cells. In turn, anti-interleukin-6 therapy ameliorated septic AKI in F4/80 MKO mice. Thus, F4/80hi macrophages express interleukin-1 receptor antagonist and constrain interleukin-6 generation from endothelial cells to limit septic AKI, representing a targetable cellular crosstalk in septic AKI. These findings are particularly relevant owing to the efficacy of anti-interleukin-6 therapies during COVID-19 infection, a disease associated with high rates of AKI and endothelial dysfunction.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Kidney Int

DOI

EISSN

1523-1755

Publication Date

March 2023

Volume

103

Issue

3

Start / End Page

514 / 528

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Sepsis
  • Receptors, Interleukin-1
  • Mice, Inbred C57BL
  • Mice
  • Macrophages
  • Kidney
  • Interleukin-6
  • Endothelial Cells
  • COVID-19
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Privratsky, J. R., Ide, S., Chen, Y., Kitai, H., Ren, J., Fradin, H., … Crowley, S. D. (2023). A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney Int, 103(3), 514–528. https://doi.org/10.1016/j.kint.2022.10.008
Privratsky, Jamie R., Shintaro Ide, Yanting Chen, Hiroki Kitai, Jiafa Ren, Helene Fradin, Xiaohan Lu, Tomokazu Souma, and Steven D. Crowley. “A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury.Kidney Int 103, no. 3 (March 2023): 514–28. https://doi.org/10.1016/j.kint.2022.10.008.
Privratsky JR, Ide S, Chen Y, Kitai H, Ren J, Fradin H, et al. A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney Int. 2023 Mar;103(3):514–28.
Privratsky, Jamie R., et al. “A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury.Kidney Int, vol. 103, no. 3, Mar. 2023, pp. 514–28. Pubmed, doi:10.1016/j.kint.2022.10.008.
Privratsky JR, Ide S, Chen Y, Kitai H, Ren J, Fradin H, Lu X, Souma T, Crowley SD. A macrophage-endothelial immunoregulatory axis ameliorates septic acute kidney injury. Kidney Int. 2023 Mar;103(3):514–528.
Journal cover image

Published In

Kidney Int

DOI

EISSN

1523-1755

Publication Date

March 2023

Volume

103

Issue

3

Start / End Page

514 / 528

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Sepsis
  • Receptors, Interleukin-1
  • Mice, Inbred C57BL
  • Mice
  • Macrophages
  • Kidney
  • Interleukin-6
  • Endothelial Cells
  • COVID-19